Jubilant Life Sciences announced that its wholly-owned subsidiary, Jubilant Pharma has successfully completed on 05 March 2019, the issuance of rated unsecured bonds (the 'Notes') to institutional investors outside India under Regulation S of the U.S. Securities Act of 1933, as amended, bearing interest at 6.00% per annum. The Notes were issued at par in a principal amount of US$200 million and will mature in March, 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
